Associate Professor of Medicine
Oncology
Dr. Faye M. Johnson, MD
|
|
Give Review
Faye Johnson is an expert in the field of Oncology. She went to Baylor College of Medicine. She over the years received 1 awards: "Regional Top Doctor". Dr. Faye M. Johnson is a published MD as well. She has 46 publications published. The latest was: Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Publications
- Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
- Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung Cancer.
- drexplorer: A tool to explore dose-response relationships and drug-drug interactions.
- A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma.
- A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer.
- Spindle Epithelial Tumor with Thymus-like Differentiation (SETTLE): A Case Report and Comprehensive Review of the Literature and Treatment Options.
- Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β3-Src Pathway.
- Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human Cancers.
- Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC.
- Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung Cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance.
- Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA re...
- Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell Carcinoma treated with definitive radiation therapy and posttreatment neck dissectio...
- Global evaluation of Eph receptors and ephrins in lung adenoCarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
- Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib.
- STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous Carcinoma.
- Regulation of SRC family kinases in human Cancers.
- Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck Cancer.
- Phase II study of dasatinib in patients with advanced non-small-cell lung Cancer.
- Epidermal growth factor receptor expression and gene copy number in the risk of oral Cancer.
- Src inhibitors in lung Cancer: current status and future directions.
- Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung Carcinoma.
- Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid Tumors.
- EphA2 in the early pathogenesis and progression of non-small cell lung Cancer.
- Reciprocal regulation of c-Src and STAT3 in non-small cell lung Cancer.
- Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung Cancer.
- Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and Cancer cell survival via altered Janus-activated kinase-S...
- Trichomegaly of the eyelashes after lung Cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
- Epithelial to mesenchymal transition in head and neck squamous Carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggre...
- Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell Carcinoma.
- A selective small molecule inhibitor of c-Met, PHA-665752, reverses Lung premalignancy induced by mutant K-ras.
- Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
- Inhibition of c-Src expression and activation in Malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
- SRC-family kinases are activated in non-small cell lung Cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.
- Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung Carcinoma.
- Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous Carcinoma cells.
- A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal Carcinoma.
- Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell Carcinoma and non-small...
- Cyclooxygenase-2 induction and prostaGlandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mes...
- A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal Carcinoma with early T status and advanced N status.
- Dose-dense therapy with a novel irinotecan regimen for small-cell lung Cancer.
- Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung Cancer.
- Correction: Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and Histologic characteristics of human Cancers.
- SRC family nonreceptor tyrosine kinases as molecular targets for Cancer therapy.
- Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
- Defining the role of the JAK-STAT pathway in head and neck and thoracic Malignancies: implications for future therapeutic approaches.
Schools
University Of Texas Medical School At Houston
Baylor College Med
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of Texas Health Science Center -
Baylor College of Medicine -
University of Texas Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1710069125 | |
| NPPES Provider LastName | JOHNSON | |
| NPPES Provider FirstName | FAYE | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 197.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 21.0 | |
| Percent Opioid Claims | 10.66 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710069125 |
| Last Name Of The Provider | JOHNSON |
| First Name Of The Provider | FAYE |
| View All |
Similar Doctors
|
|
Dr. Merrill S. Kies, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Deborah A. Thomas, MD
This Doctor is OpenDoctor Recommended.
|